One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy
One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy
复制标题
DOI：
10.1007/s00417-016-3500-1
复制
发表时间：
2017-03-01
影响因子：
2.7
通讯作者：
Nakamura, Makoto
中科院分区：
文献类型：
--
作者：
Matsumiya, Wataru;Honda, Shigeru;Nakamura, Makoto
本研究的目的是评价玻璃体内注射阿柏西普（IVA）和维替泊芬光动力疗法（vPDT）联合治疗息肉状脉络膜血管病变（PCV）的1年视力和解剖学结局，并确定良好视力结局的预测因素。来自20名未经治疗的PCV患者的20只眼睛接受了IVA和vPDT的联合治疗。随访12个月，对最佳矫正视力（BCVA）和形态学参数（包括吲哚菁绿绿色血管造影（ICGA）中的息肉样病变）进行了评价，平均logMAR BCVA从基线时的0.30显著提高到3个月时的0.20和12个月时的0.18。平均中央视网膜厚度在3个月和12个月时也显著改善。在ICGA中，3个月时20只眼中有14只眼（70%）息肉样病变完全消退，12个月时18只眼中有14只眼（78%）息肉样病变完全消退，但2只眼未进行ICGA。在多变量逻辑回归分析中，发现基线最大线性维度是12个月时良好视力改善的显著预测因素（从基线改善0.3 LogMAR单位）。在这项研究中，IVA和vPDT联合治疗在12个月的随访期内使未经治疗的PCV患者的视力和解剖学改善。
The purpose of the study was to evaluate the 1-year visual and anatomical outcomes of combination therapy with intravitreal aflibercept (IVA) and verteporfin photodynamic therapy (vPDT) for polypoidal choroidal vasculopathy (PCV), and to determine the predictors of a good visual outcome.This was a prospective case-series study. Twenty eyes from 20 treatment-na < ve PCV patients were treated with combination therapy with IVA and vPDT. Best-corrected visual acuity (BCVA) and morphological parameters including polypoidal lesions in indocyanine green angiography (ICGA) were evaluated over 12 months of follow-up.The mean logMAR BCVA was significantly improved from 0.30 at baseline to 0.20 at 3 months and 0.18 at 12 months. The mean central retinal thickness was also significantly improved at 3 months and at 12 months. In ICGA, complete regression of polypoidal lesions was found in 14 out of 20 eyes (70 %) at 3 months and in 14 out of 18 eyes (78 %) at 12 months although no ICGA were done on two eyes. In the multivariate logistic regression analyses, the baseline greatest linear dimension was found as a significant predictive factor for good visual improvement (ae 0.3 LogMAR units improvement from baseline) at 12 months.In this study, combination therapy with IVA and vPDT gave visual and anatomical improvements to treatment-na < ve PCV patients over 12 months of follow-up period.